FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2533994927> ?p ?o ?g. }

• W2533994927 endingPage "84374" @default.
• W2533994927 startingPage "84359" @default.
• W2533994927 abstract "// Erika Heninger 1, 3 , Timothy E.G. Krueger 3 , Stephanie M. Thiede 1, 3 , Jamie M. Sperger 1, 3 , Brianna L. Byers 3 , Madison R. Kircher 3 , David Kosoff 1, 3 , Bing Yang 2, 3 , David F. Jarrard 2, 3 , Douglas G. McNeel 1, 3 , Joshua M. Lang 1, 3 1 Department of Medicine, University of Wisconsin, Madison, Madison, WI 53705, USA 2 Department of Urology, University of Wisconsin, Madison, Madison, WI 53705, USA 3 University of Wisconsin Carbone Cancer Center, Madison, Madison, WI 53705, USA Correspondence to: Joshua M. Lang, email: jmlang@medicine.wisc.edu Keywords: cancer testis antigen, prostate cancer, epigenetics, tumor immunotherapy, methylation Received: April 22, 2016      Accepted: October 11, 2016      Published: October 17, 2016 ABSTRACT Immune tolerance to self-antigens can limit robust anti-tumor immune responses in the use of tumor vaccines. Expression of novel tumor associated antigens can improve immune recognition and lysis of tumor cells. The cancer-testis antigen (CTA) family of proteins has been hypothesized to be an ideal class of antigens due to tumor-restricted expression, a subset of which have been found to induce antibody responses in patients with prostate disease. We demonstrate that CTA expression is highly inducible in five different Prostate Cancer (PC) cell lines using a hypomethylating agent 5-Aza-2′-deoxycytidine (5AZA) and/or a histone deacetylase inhibitor LBH589. These CTAs include NY-ESO1, multiple members of the MAGE and SSX families and NY-SAR35. A subset of CTAs is synergistically induced by the combination of 5AZA and LBH589. We developed an ex vivo organ culture using human PC biopsies for ex vivo drug treatments to evaluate these agents in clinical samples. These assays found significant induction of SSX2 in 9/9 distinct patient samples and NY-SAR35 in 7/9 samples. Further, we identify expression of SSX2 in circulating tumor cells (CTC) from patients with advanced PC. These results indicate that epigenetic modifying agents can induce expression of a broad range of neoantigens in human PC and may serve as a useful adjunctive therapy with novel tumor vaccines and checkpoint inhibitors." @default.
• W2533994927 created "2016-10-28" @default.
• W2533994927 creator A5010695005 @default.
• W2533994927 creator A5016291949 @default.
• W2533994927 creator A5020045862 @default.
• W2533994927 creator A5021686685 @default.
• W2533994927 creator A5037053199 @default.
• W2533994927 creator A5046457789 @default.
• W2533994927 creator A5050820010 @default.
• W2533994927 creator A5057872089 @default.
• W2533994927 creator A5073338534 @default.
• W2533994927 creator A5073369544 @default.
• W2533994927 creator A5080086801 @default.
• W2533994927 date "2016-10-17" @default.
• W2533994927 modified "2023-09-23" @default.
• W2533994927 title "Inducible expression of cancer-testis antigens in human prostate cancer" @default.
• W2533994927 cites W1503744211 @default.
• W2533994927 cites W1529128810 @default.
• W2533994927 cites W1544486867 @default.
• W2533994927 cites W1579417540 @default.
• W2533994927 cites W1602172318 @default.
• W2533994927 cites W1886848895 @default.
• W2533994927 cites W1912176663 @default.
• W2533994927 cites W1940135647 @default.
• W2533994927 cites W1965390250 @default.
• W2533994927 cites W1970062306 @default.
• W2533994927 cites W1972173313 @default.
• W2533994927 cites W1973588440 @default.
• W2533994927 cites W1973598753 @default.
• W2533994927 cites W1974885520 @default.
• W2533994927 cites W1978485838 @default.
• W2533994927 cites W1986592841 @default.
• W2533994927 cites W1989752811 @default.
• W2533994927 cites W1996972360 @default.
• W2533994927 cites W1998561392 @default.
• W2533994927 cites W1999042146 @default.
• W2533994927 cites W1999389341 @default.
• W2533994927 cites W2006987944 @default.
• W2533994927 cites W2012034410 @default.
• W2533994927 cites W2014748730 @default.
• W2533994927 cites W2022394909 @default.
• W2533994927 cites W2039138842 @default.
• W2533994927 cites W2039695859 @default.
• W2533994927 cites W2044274117 @default.
• W2533994927 cites W2045345013 @default.
• W2533994927 cites W2048484529 @default.
• W2533994927 cites W2051069352 @default.
• W2533994927 cites W2051604747 @default.
• W2533994927 cites W2051674693 @default.
• W2533994927 cites W2057843583 @default.
• W2533994927 cites W2059482310 @default.
• W2533994927 cites W2078014810 @default.
• W2533994927 cites W2080388405 @default.
• W2533994927 cites W2098337213 @default.
• W2533994927 cites W2103470676 @default.
• W2533994927 cites W2106497182 @default.
• W2533994927 cites W2108244474 @default.
• W2533994927 cites W2110037434 @default.
• W2533994927 cites W2110913360 @default.
• W2533994927 cites W2111710631 @default.
• W2533994927 cites W2112185172 @default.
• W2533994927 cites W2112680536 @default.
• W2533994927 cites W2115575801 @default.
• W2533994927 cites W2121017621 @default.
• W2533994927 cites W2121219667 @default.
• W2533994927 cites W2130588827 @default.
• W2533994927 cites W2135844841 @default.
• W2533994927 cites W2136267518 @default.
• W2533994927 cites W2137547257 @default.
• W2533994927 cites W2142190430 @default.
• W2533994927 cites W2147711601 @default.
• W2533994927 cites W2150125378 @default.
• W2533994927 cites W2151284873 @default.
• W2533994927 cites W2153901235 @default.
• W2533994927 cites W2157120289 @default.
• W2533994927 cites W2159173286 @default.
• W2533994927 cites W2162184070 @default.
• W2533994927 cites W2165263439 @default.
• W2533994927 cites W2171297632 @default.
• W2533994927 cites W2282097674 @default.
• W2533994927 cites W2282215456 @default.
• W2533994927 cites W2286173468 @default.
• W2533994927 cites W2342335701 @default.
• W2533994927 cites W2401131132 @default.
• W2533994927 cites W2411367694 @default.
• W2533994927 cites W2412989557 @default.
• W2533994927 cites W2417171055 @default.
• W2533994927 cites W2463477049 @default.
• W2533994927 cites W2497447644 @default.
• W2533994927 cites W2387577678 @default.
• W2533994927 doi "https://doi.org/10.18632/oncotarget.12711" @default.
• W2533994927 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5341296" @default.
• W2533994927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27769045" @default.
• W2533994927 hasPublicationYear "2016" @default.
• W2533994927 type Work @default.
• W2533994927 sameAs 2533994927 @default.
• W2533994927 citedByCount "16" @default.
• W2533994927 countsByYear W25339949272017 @default.

• next